The biopharma Atai Life Sciences (Nasdaq:ATAI) subsidiary GABA Therapeutics is sharing positive results from a Phase 1 study of GRX-917, a deuterated form of etifoxine, which the German firm Hoechst developed in the 1960s. Sanofi-Aventis eventually subsumed Hoechst in 2004.
Atai investigated the safety, tolerability and pharmacokinetic profile of orally administered GRX-917 in a Phase 1 study.
The company is developing GRX-917 for generalized anxiety disorder (GAD).
An improved safety profile than benzodiazepines?The company believes the GRX-917 could have a better safety profile than traditional benzodiazepines.
“Based on etifoxine’s safety and efficacy profile, we believe GRX-917 will offer a differentiated treatment for GAD with fewer side effects—such as sedation, respiratory depression, and withdrawal,” said Dr. Mario Saltarelli, chief medical officer of GABA Therapeutics.
The company noted that the drug candidate was well tolerated.<…